ES2176668T3 - Aminoacidos ciclicos novedosos como agentes farmaceuticos. - Google Patents

Aminoacidos ciclicos novedosos como agentes farmaceuticos.

Info

Publication number
ES2176668T3
ES2176668T3 ES97901385T ES97901385T ES2176668T3 ES 2176668 T3 ES2176668 T3 ES 2176668T3 ES 97901385 T ES97901385 T ES 97901385T ES 97901385 T ES97901385 T ES 97901385T ES 2176668 T3 ES2176668 T3 ES 2176668T3
Authority
ES
Spain
Prior art keywords
amino acids
pharmaceutical agents
alterations
new
new cycling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97901385T
Other languages
English (en)
Inventor
David C Horwell
Justin S Bryans
Clare O Kneen
Giles S Ratcliffe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2176668T3 publication Critical patent/ES2176668T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS AMINOACIDOS CICLICOS DE FORMULA (IA) O (IB), QUE SON UTILES COMO AGENTES PARA EL TRATAMIENTO DE LA EPILEPSIA, ATAQUES DE DEBILIDAD, HIPOQUINESIA, ALTERACIONES CRANEALES, ALTERACIONES NEURODEGENERATIVAS, DEPRESION, ANSIEDAD, PANICO, DOLOR Y ALTERACIONES NEUROPATOLOGICAS. SE DESCRIBEN ASIMISMO PROCEDIMIENTOS DE PREPARACION E INTERMEDIARIOS UTILES EN LA PREPARACION DE DICHOS COMPUESTOS.
ES97901385T 1996-02-07 1997-01-02 Aminoacidos ciclicos novedosos como agentes farmaceuticos. Expired - Lifetime ES2176668T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1127896P 1996-02-07 1996-02-07

Publications (1)

Publication Number Publication Date
ES2176668T3 true ES2176668T3 (es) 2002-12-01

Family

ID=21749660

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97901385T Expired - Lifetime ES2176668T3 (es) 1996-02-07 1997-01-02 Aminoacidos ciclicos novedosos como agentes farmaceuticos.

Country Status (22)

Country Link
US (1) US5929088A (es)
EP (1) EP0888325B1 (es)
JP (1) JP2000511877A (es)
KR (1) KR19990082349A (es)
AT (1) ATE218135T1 (es)
AU (1) AU720628B2 (es)
BR (1) BR9707366A (es)
CA (1) CA2244708A1 (es)
CZ (1) CZ296052B6 (es)
DE (1) DE69712877T2 (es)
DK (1) DK0888325T3 (es)
EA (1) EA001534B1 (es)
ES (1) ES2176668T3 (es)
HU (1) HUP9901074A3 (es)
IL (1) IL125562A (es)
NO (1) NO983612L (es)
NZ (1) NZ326669A (es)
PL (1) PL328432A1 (es)
PT (1) PT888325E (es)
SK (1) SK282665B6 (es)
WO (1) WO1997029101A1 (es)
ZA (1) ZA97991B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
NZ502786A (en) * 1997-09-18 2002-05-31 Warner Lambert Co Preparation of gabapentin analogues comprised of adding cyclohexanone to sodium hydride and finally heating the formed lactam in HCl and dioxan
US6984659B2 (en) 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
DE19751062A1 (de) 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
KR20010033153A (ko) * 1997-12-16 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 4(3)-치환-4(3)-아미노메틸-(티오)피란 또는 -피페리딘유도체(=가바펜틴 동족체), 그의 제법 및 신경 질환 치료용도
AU2001247762A1 (en) * 2000-03-28 2001-10-08 Delorenzo, Robert, J Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
EP1361847A2 (en) 2000-10-06 2003-11-19 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
US7420002B2 (en) 2001-06-11 2008-09-02 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA03011566A (es) 2001-06-11 2004-10-28 Xenoport Inc Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7026351B2 (en) 2002-03-20 2006-04-11 Xenoport, Inc. Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
AU2003243180A1 (en) 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US20040092498A1 (en) * 2002-08-16 2004-05-13 David Blakemore Substituted glycine derivatives for use as medicaments
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
DE60332387D1 (de) 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20060119971A (ko) 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
DE602004024317D1 (de) 2003-09-12 2010-01-07 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
WO2005027850A2 (en) 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
MXPA06004088A (es) 2003-10-14 2006-06-27 Xenoport Inc Forma cristalina de un analogo del acido gamma-aminobutirico.
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
ATE511860T1 (de) 2006-12-22 2011-06-15 Recordati Ireland Ltd Kombinationstherapie für erkrankungen der unteren harnwege mit 2 liganden und nsar
WO2009024615A1 (en) * 2007-08-23 2009-02-26 Novartis Ag Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors
EP2250143B1 (en) 2008-01-25 2016-04-20 XenoPort, Inc. Method for the enzymatic kinetic resolution of acyloxyalkyl thiocarbonates used for the synthesis of acyloxyalkyl carbamates
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
WO2010084797A1 (ja) * 2009-01-21 2010-07-29 第一三共株式会社 含ヘテロ原子化合物
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
WO2014117176A1 (en) 2013-01-28 2014-07-31 Lopez Hector L Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor
CA3099775A1 (en) 2018-05-14 2019-11-21 Xgene Pharmaceutical Inc. Process for making 1-(acyloxy)-alkyl-carabmate drug conjugates of naproxen and pregabalin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
KR970010173B1 (ko) * 1991-07-09 1997-06-21 닛뽕소다 가부시끼가이샤 함헤테로 시클로헥산디온 유도체, 그의 제조방법 및 제초제
US5514801A (en) * 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors
GB9314758D0 (en) * 1993-07-16 1993-08-25 Wyeth John & Brother Ltd Heterocyclic derivatives
US5527194A (en) * 1994-02-02 1996-06-18 Brunswick Corporation Thrust sensor for marine drives
US5491152A (en) * 1994-03-23 1996-02-13 The Du Pont Merck Pharmaceutical Company Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis
US5760006A (en) * 1997-06-23 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating psoriasis

Also Published As

Publication number Publication date
KR19990082349A (ko) 1999-11-25
CZ245298A3 (cs) 1998-11-11
CA2244708A1 (en) 1997-08-14
DE69712877T2 (de) 2002-11-14
NZ326669A (en) 2001-05-25
NO983612L (no) 1998-10-06
ATE218135T1 (de) 2002-06-15
SK282665B6 (sk) 2002-11-06
JP2000511877A (ja) 2000-09-12
AU720628B2 (en) 2000-06-08
SK106798A3 (en) 1999-07-12
PL328432A1 (en) 1999-02-01
IL125562A0 (en) 1999-03-12
US5929088A (en) 1999-07-27
NO983612D0 (no) 1998-08-06
AU1529597A (en) 1997-08-28
BR9707366A (pt) 1999-07-20
DK0888325T3 (da) 2002-09-16
IL125562A (en) 2001-08-08
HUP9901074A2 (hu) 2001-04-28
DE69712877D1 (de) 2002-07-04
PT888325E (pt) 2002-10-31
EA001534B1 (ru) 2001-04-23
EP0888325B1 (en) 2002-05-29
EA199800682A1 (ru) 1999-02-25
CZ296052B6 (cs) 2005-12-14
ZA97991B (en) 1997-08-15
EP0888325A1 (en) 1999-01-07
WO1997029101A1 (en) 1997-08-14
HUP9901074A3 (en) 2001-08-28

Similar Documents

Publication Publication Date Title
ES2167717T3 (es) Nuevos aminoacidos ciclicos sustituidos como agentes farmaceuticos.
GT200000183AA (es) Aminoacidos biciclicos como agentes farmaceuticos
PA8543501A1 (es) Aminoácidos bicíclicos o tricíclicos condensados
BR9712651A (pt) ‡cidos gama-aminobutìricos substituìdos com agentes farmacêuticos.
HN1999000072A (es) Preparaciones farmaceuticas estabilizadas de gaba pentina y proceso para prepararla.
UY24354A1 (es) Composiciones farmacéuticas que contienen epinastina
BR9910697A (pt) Compostos aminoácidos comprimidos estruturalmente tendo afinidade à subunidade alfa2delta de um canal de cálcio
DK0888325T3 (da) Cykliske aminosyrer som farmaceutiske midler
AR032293A1 (es) Estuche farmaceutico
PT1296948E (pt) Nova formas cristalina gama do sal de ter.-butilamina do perindopril processo para a sua preparacao e as composicoes farmaceuticas que a contem
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
ES2164842T3 (es) Procedimiento para la preparacion de composiciones de microcapsulas.
GT199800037A (es) Combinaciones para diabetes de sulfonilurea - glitazona.
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
HN1998000174A (es) Combinacion eficaz para el tratamiento de la impotencia
PA8452701A1 (es) Agonistas de prostaglandinas
PT938326E (pt) Fosfopeptidos de sintese para o tratamento de doencas dos ossos
BR9607965A (pt) Composto composição farmacêutica e processo para tratar uma doença parasítica em um mamífero
WO2000037422A3 (en) Ion channel modulating agents
WO2002057215A3 (en) Sodium channel modulators
IL172783A0 (en) Rasgap derived peptide for selectively killing cancer cells
MX9704490A (es) Tratamiento terapeutico combinado de las patologias hiperproliferativas.
ATE208200T1 (de) Transdermales therapeutisches system (tts) zur verabreichung von testosteron
ES2184300T3 (es) Derivados de aminoacidos utiles para tratar el accidente vascular encefalico.
UA89753C2 (ru) Применение модафинила и антидепрессанта при лечении депрессии и для сокращения времени до начала действия антидепрессанта